Hepatic Encephalopathy and The Emerging Role of Medicinal Plants: An Integrative Approach to Neuro Metabolic Dysfunction
Keywords:
Antioxidant therapy, Cognitive dysfunction, Herbal medicine, Neuroinflammation, Oxidative stress, Phytotherapy.Abstract
A multifaceted neurological condition, hepatic encephalopathy (HE) is complex that arises as a result of severe liver damage. Traditionally viewed as a reversible metabolic condition, recent findings highlight the part of neuroinflammation, oxidative stress, and disturbed blood-brain barrier in its progression. Current treatment approaches largely focus on ammonia reduction but fail to fully address underlying neuronal and inflammatory imbalances. Emerging evidence supports the use of medicinal plants with neuroprotective, antioxidant, and anti-inflammatory properties as complementary therapies in HE. Various phytochemicals derived from plants like Moringa oleifera, Ashwagandha, and Berberine have demonstrated promising effects in animal models, improving cognitive function and reducing biochemical and histopathological damage. This review synthesizes current insights into HE pathophysiology and highlights the integrative role of plant-based interventions as a future therapeutic strategy.
Downloads
References
Rose, C. F., Amodio, P., Bajaj, J. S., Dhiman, R. K., Montagnese, S., Taylor-Robinson, S. D., ... & Jalan, R. (2020). Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. Journal of hepatology, 73(6), 1526-1547.
Hadjihambi, A., Arias, N., Sheikh, M., & Jalan, R. (2018). Hepatic encephalopathy: a critical current review. Hepatology international, 12, 135-147.
Ferenci, P. (2017). Hepatic encephalopathy. Gastroenterology report, 5(2), 138-147.
Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K. D., ... & Wong, P. (2014). Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology, 60(2), 715-735.
Tapper, E. B., Parikh, N. D., Waljee, A. K., Volk, M., Carlozzi, N. E., & Lok, A. S. (2018). Diagnosis of minimal hepatic encephalopathy: a systematic review of point-of-care diagnostic tests. Official journal of the American College of Gastroenterology| ACG, 113(4), 529-538.
Román, E., Córdoba, J., Torrens, M., Torras, X., Villanueva, C., Vargas, V., ... & Soriano, G. (2011). Minimal hepatic encephalopathy is associated with falls. Official journal of the American College of Gastroenterology| ACG, 106(3), 476-482.
Tapper, E. B., Henderson, J. B., Parikh, N. D., Ioannou, G. N., & Lok, A. S. (2019). Incidence of and risk factors for hepatic encephalopathy in a population‐based cohort of Americans with cirrhosis. Hepatology communications, 3(11), 1510-1519.
Louissaint, J., Deutsch-Link, S., & Tapper, E. B. (2022). Changing epidemiology of cirrhosis and hepatic encephalopathy. Clinical Gastroenterology and Hepatology, 20(8), S1-S8.
Ferenci, P., Lockwood, A., Mullen, K., Tarter, R., Weissenborn, K., & Blei, A. T. (2002). Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology, 35(3), 716-721.
Ong, J. P., Aggarwal, A., Krieger, D., Easley, K. A., Karafa, M. T., Van Lente, F., ... & Mullen, K. D. (2003). Correlation between ammonia levels and the severity of hepatic encephalopathy. The American journal of medicine, 114(3), 188-193.
Montagnese, S., De Rui, M., Angeli, P., & Amodio, P. (2017). Neuropsychiatric performance in patients with cirrhosis: Who is “normal”?. Journal of hepatology, 66(4), 825-835.
Ortiz, M., Jacas, C., & Córdoba, J. (2005). Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. Journal of hepatology, 42(1), S45-S53.
Schiff, S., Casa, M., Di Caro, V., Aprile, D., Spinelli, G., De Rui, M., Angeli, P., Amodio, P., & Montagnese, S. (2016). A low-cost, user-friendly electroencephalographic recording system for the assessment of hepatic encephalopathy. Hepatology (Baltimore, Md.), 63(5), 1651–1659.
Montagnese, S., Amodio, P., & Morgan, M. Y. (2004). Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach. Metabolic brain disease, 19, 281-312.
Prakash, R., & Mullen, K. D. (2010). Mechanisms, diagnosis and management of hepatic encephalopathy. Nature reviews Gastroenterology & hepatology, 7(9), 515-525.
Hartmann, I. J., Groeneweg, M., Quero, J. C., Beijeman, S. J., De Man, R. A., Hop, W. C., & Schalm, S. W. (2000). The prognostic significance of subclinical hepatic encephalopathy. Official journal of the American College of Gastroenterology| ACG, 95(8), 2029-2034
Yen, C. L., & Liaw, Y. F. (1990). Somatosensory evoked potentials and number connection test in the detection of subclinical hepatic encephalopathy. Hepato-gastroenterology, 37(3), 332-334.
Gairing, S. J., Mangini, C., Zarantonello, L., Gioia, S., Nielsen, E. J., Danneberg, S., ... & Labenz, C. (2024). Minimal hepatic encephalopathy is associated with a higher risk of overt hepatic encephalopathy and poorer survival. Journal of internal medicine, 295 (3), 331-345.
Romero-Gómez, M., Grande, L., Camacho, I., Benitez, S., Irles, J. A., & Castro, M. (2002). Altered response to oral glutamine challenge as prognostic factor for overt episodes in patients with minimal hepatic encephalopathy. Journal of hepatology, 37(6), 781-787.
Amodio, P., Del Piccolo, F., Marchetti, P., Angeli, P., Iemmolo, R., Caregaro, L., ... & Gatta, A. (1999). Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests. Hepatology, 29(6), 1662-1667.
Tranah, T. H., Vijay, G. K. M., Ryan, J. M., & Shawcross, D. L. (2013). Systemic inflammation and ammonia in hepatic encephalopathy. Metabolic brain disease, 28, 1-5.
Vásconez, C., Elizalde, J. I., Llach, J., Ginès, A., de la Rosa, C., Fernández, R. M., ... & Terés, J. (1999). Helicobacter pylori, hyperammonemia and subclinical portosystemic encephalopathy: effects of eradication. Journal of hepatology, 30(2), 260-264
Aldridge, D. R., Tranah, E. J., & Shawcross, D. L. (2015). Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. Journal of clinical and experimental hepatology, 5(Suppl 1), S7–S20.
Ciećko-Michalska, I., Szczepanek, M., Słowik, A., & Mach, T. (2012). Pathogenesis of hepatic encephalopathy. Gastroenterology research and practice, 2012, 642108.
Ochoa-Sanchez, R., & Rose, C. F. (2018). Pathogenesis of Hepatic Encephalopathy in Chronic Liver Disease. Journal of clinical and experimental hepatology, 8(3), 262–271.
Ferenci P. (2004). Pathophysiology and clinical features of Wilson disease. Metabolic brain disease, 19(3-4), 229–239
Sen, B. K., Pan, K., & Chakravarty, A. (2025). Hepatic Encephalopathy: Current Thoughts on Pathophysiology and Management. Current Neurology and Neuroscience Reports, 25(1), 28.
Butterworth, R. F. (2019). L-Ornithine L-Aspartate (LOLA) for the treatment of hepatic encephalopathy in cirrhosis: Novel insights and translation to the clinic. Drugs, 79(Suppl 1), 1-3.
Dalal R, McGee RG, Riordan SM, Webster AC (2017). Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev ;2:CD008716
Mullen, K., & Prakash, R. (2010). Rifaximin for the treatment of hepatic encephalopathy. Expert review of gastroenterology & hepatology, 4(6), 665-677.
Bémeur, C., Desjardins, P., & Butterworth, R. F. (2010). Role of nutrition in the management of hepatic encephalopathy in end‐stage liver failure. Journal of nutrition and metabolism, 2010(1), 489823.
Merli, M., & Riggio, O. (2009). Dietary and nutritional indications in hepatic encephalopathy. Metabolic brain disease, 24, 211-221.
Riordan, S. M., Williams, R., Riordan, S. M., Williams, R., Sharma, B. C., Sharma, P., ... & Malaguarnera, G. (2010). Gut flora and hepatic encephalopathy in patients with cirrhosis. New England Journal of Medicine, 362(12), 1140.
Shen, Y. C., Chang, Y. H., Fang, C. J., & Lin, Y. S. (2019). Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis. Nutrition journal, 18, 1-9.
Phongsamran, P. V., Kim, J. W., Abbott, J. C., & Rosenblatt, A. (2010). Pharmacotherapy for hepatic encephalopathy. Drugs, 70, 1131-1148.
Liu, A., Yoo, E. R., Siddique, O., Perumpail, R. B., Cholankeril, G., & Ahmed, A. (2017). Hepatic encephalopathy: what the multidisciplinary team can do. Journal of Multidisciplinary Healthcare, 113-119.
Bajaj, J. S., Wade, J. B., Gibson, D. P., Heuman, D. M., Thacker, L. R., Sterling, R. K., ... & Sanyal, A. J. (2011). The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Official journal of the American College of Gastroenterology| ACG, 106(9), 1646-1653.
Weissenborn, K., Giewekemeyer, K., Heidenreich, S., Bokemeyer, M., Berding, G., & Ahl, B. (2005). Attention, memory, and cognitive function in hepatic encephalopathy. Metabolic brain disease, 20, 359-367.
Gabriel, M. M., Kircheis, G., Hardtke, S., Markwardt, D., Buggisch, P., Mix, H., ... & Weissenborn, K. (2021). Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study. European Journal of Gastroenterology & Hepatology, 33(9), 1185-1193.
Azhari, H., & Swain, M. G. (2018). Role of peripheral inflammation in hepatic encephalopathy. Journal of clinical and experimental hepatology, 8(3), 281-285.
Felipo, V. (2013). Hepatic encephalopathy: effects of liver failure on brain function. Nature Reviews Neuroscience, 14(12), 851-858.
Neff, G., & III, W. Z. (2018). Systematic review of the economic burden of overt hepatic encephalopathy and pharmacoeconomic impact of rifaximin. Pharmacoeconomics, 36, 809-822.
Sharma, P., & Sharma, B. C. (2015). Management of overt hepatic encephalopathy. Journal of clinical and experimental hepatology, 5, S82-S87.
Kalaitzakis, E., & Björnsson, E. (2007). Lactulose treatment for hepatic encephalopathy, gastrointestinal symptoms, and health‐related quality of life. Hepatology, 46(3), 949-950.
Swaminathan, M., Ellul, M. A., & Cross, T. J. (2018). Hepatic encephalopathy: current challenges and future prospects. Hepatic medicine: evidence and research, 1-11.
Cordova-Gallardo, J., Vargas-Beltran, A. M., Armendariz-Pineda, S. M., Ruiz-Manriquez, J., Ampuero, J., & Torre, A. (2024). Brain reserve in hepatic encephalopathy: pathways of damage and preventive strategies through lifestyle and therapeutic interventions. Annals of Hepatology, 101740.
Bajaj, J. S., O’Leary, J. G., Tandon, P., Wong, F., Kamath, P. S., Biggins, S. W., ... & Reddy, K. R. (2019). Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi‐centre cohort. Alimentary pharmacology & therapeutics, 49(12), 1518-1527.
Gupta, K., & Mamidi, P. (2023). Ayurvedic management of chronic liver disease with portal hypertension and hepatic encephalopathy-A case report. Int J Complement Alt Med, 16(5), 240-244.
Zheng, S., Xue, C., Li, S., Zao, X., Li, X., Liu, Q., ... & Ye, Y. (2024). Liver cirrhosis: current status and treatment options using western or traditional Chinese medicine. Frontiers in Pharmacology, 15, 1381476.
Fawaz Ahmed, A. A., Abdelhakam, S. M., Esmat, I. M., Mohamed, N. R., Ashoor, T. M., & Ebrahim Elsayed, A. E. (2024). Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients with Hepatic Encephalopathy: A Randomized Controlled Trial. QJM: An International Journal of Medicine, 117(Supplement_2), hcae175-009.
Mahmoud, M. S., El-Kott, A. F., AlGwaiz, H. I., & Fathy, S. M. (2022). Protective effect of Moringa oleifera Lam. leaf extract against oxidative stress, inflammation, depression, and apoptosis in a mouse model of hepatic encephalopathy. Environmental Science and Pollution Research, 29(55), 83783-83796.
Baek, S. Y., Lee, E. H., Oh, T. W., Do, H. J., Kim, K. Y., Park, K. I., & Kim, Y. W. (2020). Network pharmacology-based approaches of rheum undulatum linne and glycyrriza uralensis fischer imply their regulation of liver failure with hepatic encephalopathy in mice. Biomolecules, 10(3), 437.
El-Baz, F. K., Elgohary, R., & Salama, A. (2021). Amelioration of hepatic encephalopathy using Dunaliella salina microalgae in rats: modulation of hyperammonemia/TLR4. Biomed Research International, 2021(1), 8843218.
Du, Y., Wang, M., Xu, J., Zhong, R., Jia, J., Huang, J., ... & Fu, L. (2023). Investigation of therapeutic effects of rhubarb decoction retention enema on minimal hepatic encephalopathy in rats based on 16S rDNA gene sequencing and bile acid metabolomics. Journal of Pharmaceutical and Biomedical Analysis, 230, 115392.
Hajipour, S., Farbood, Y., Dianat, M., Nesari, A., & Sarkaki, A. (2023). Effect of berberine against cognitive deficits in rat model of thioacetamide-induced liver cirrhosis and hepatic encephalopathy (behavioral, biochemical, molecular and histological evaluations). Brain Sciences, 13(6), 944.
Shirmohammadi Zeshkian, F., & Srinivasan, R. (2024). Ameliorating effects of Myrcene, a monoterpene in many plants, on thioacetamide-induced acute hepatic encephalopathy in rats. Archives of Razi Institute, 79(3), 617-622.
El-Hagrassi, A. M., Osman, A. F., El-Naggar, M. E., Mowaad, N. A., Khalil, S., & Hamed, M. A. (2022). Phytochemical constituents and protective efficacy of Schefflera arboricola L. leaves extract against thioacetamide-induced hepatic encephalopathy in rats. Biomarkers, 27(4), 375-394.
Sun, X., Lv, Y., Huang, L., Gao, H., Ren, C., Li, J., ... & Xiao, J. (2020). Pro-inflammatory cytokines serve as communicating molecules between the liver and brain for hepatic encephalopathy pathogenesis and Lycium barbarum polysaccharides protection. Journal of ethnopharmacology, 248, 112357.
AboZaid, O. A., Mansour, S. Z., & El-Gendey, A. E. (2015). Biochemical markers to the protective effects of Fructus Piperis Longi extract on Hepatic encephalopathy in rats. Benha Veterinary Medical Journal, 29(2), 283-296.
Deniz, G. Y. (2018). Protective mechanism of Urtica dioica on carbon tetrachloride-induced hepatic encephalopathy in rats. Van Veterinary Journal, 29(2), 77-81.
Mostafa, R. E., Salama, A. A., Abdel-Rahman, R. F., & Ogaly, H. A. (2017). Hepato-and neuro-protective influences of biopropolis on thioacetamide-induced acute hepatic encephalopathy in rats. Canadian journal of physiology and pharmacology, 95(5), 539-547.
Hajipour, S., Sarkaki, A., Dianat, M., Rashno, M., Khorsandi, L. S., & Farbood, Y. (2021). The effects of thymoquinone on memory impairment and inflammation in rats with hepatic encephalopathy induced by thioacetamide. Metabolic Brain Disease, 36, 991-1002.
Lu, L., Wu, C., Lu, B. J., Xie, D., Wang, Z., Azami, N. L. B., ... & Sun, M. Y. (2020). BabaoDan cures hepatic encephalopathy by decreasing ammonia levels and alleviating inflammation in rats. Journal of ethnopharmacology, 249, 112301.
Khalil, H. M., Eliwa, H. A., El-Shiekh, R. A., Al-Mokaddem, A. K., Hassan, M., Tawfek, A. M., & El-Maadawy, W. H. (2021). Ashwagandha (Withania somnifera) root extract attenuates hepatic and cognitive deficits in thioacetamide-induced rat model of hepatic encephalopathy via induction of Nrf2/HO-1 and mitigation of NF-κB/MAPK signaling pathways. Journal of ethnopharmacology, 277, 114141.
Sedik, A. A., Hussein, D. T., Fathy, K., & Mowaad, N. A. (2024). Neuroprotective and cognitive enhancing effects of herbecetin against thioacetamide induced hepatic encephalopathy in rats via upregulation of AMPK and SIRT1 signaling pathways. Scientific Reports, 14(1), 11396.
Baraka, S. M., Saleh, D. O., Ghaly, N. S., Melek, F. R., El Din, A. A. G., Khalil, W. K., ... & Medhat, A. M. (2020). Flavonoids from Barnebydendron riedelii leaf extract mitigate thioacetamide-induced hepatic encephalopathy in rats: the interplay of NF-κB/IL-6 and Nrf2/HO-1 signaling pathways. Bioorganic Chemistry, 105, 104444.
El-Marasy, S. A., El Awdan, S. A., & Abd-Elsalam, R. M. (2019). Protective role of chrysin on thioacetamide-induced hepatic encephalopathy in rats. Chemico-Biological Interactions, 299, 111-119.
Sathyasaikumar, K. V., Swapna, I., Reddy, P. V. B., Murthy, C. R., Roy, K. R., Gupta, A. D., ... & Reddanna, P. (2007). Co-administration of C-Phycocyanin ameliorates thioacetamide-induced hepatic encephalopathy in Wistar rats. Journal of the neurological sciences, 252(1), 67-75.
Ali, S. A., & Datusalia, A. K. (2024). Protective effects of Tinospora cordifolia miers extract against hepatic and neurobehavioral deficits in thioacetamide-induced hepatic encephalopathy in rats via modulating hyperammonemia and glial cell activation. Journal of ethnopharmacology, 323, 117700.
Abdelghffar, E. A., El-Nashar, H. A., Fayez, S., Obaid, W. A., & Eldahshan, O. A. (2022). Ameliorative effect of oregano (Origanum vulgare) versus silymarin in experimentally induced hepatic encephalopathy. Scientific Reports, 12(1), 17854.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Tropical Journal of Pharmaceutical and Life Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
